» Articles » PMID: 14523773

Rift Valley Fever Epidemic in Saudi Arabia: Epidemiological, Clinical, and Laboratory Characteristics

Overview
Journal Clin Infect Dis
Date 2003 Oct 3
PMID 14523773
Citations 245
Authors
Affiliations
Soon will be listed here.
Abstract

This cohort descriptive study summarizes the epidemiological, clinical, and laboratory characteristics of the Rift Valley fever (RVF) epidemic that occurred in Saudi Arabia from 26 August 2000 through 22 September 2001. A total of 886 cases were reported. Of 834 reported cases for which laboratory results were available, 81.9% were laboratory confirmed, of which 51.1% were positive for only RVF immunoglobulin M, 35.7% were positive for only RVF antigen, and 13.2% were positive for both. The mean age (+/- standard deviation) was 46.9+/-19.4 years, and the ratio of male to female patients was 4:1. Clinical and laboratory features included fever (92.6% of patients), nausea (59.4%), vomiting (52.6%), abdominal pain (38.0%), diarrhea (22.1%), jaundice (18.1%), neurological manifestations (17.1%), hemorrhagic manifestations (7.1%), vision loss or scotomas (1.5%), elevated liver enzyme levels (98%), elevated lactate dehydrogenase level (60.2%), thrombocytopenia (38.4%), leukopenia (39.7%), renal impairment or failure (27.8%), elevated creatine kinase level (27.3%), and severe anemia (15.1%). The mortality rate was 13.9%. Bleeding, neurological manifestations, and jaundice were independently associated with a high mortality rate. Patients with leukopenia had significantly a lower mortality rate than did those with a normal or high leukocyte count (2.3% vs. 27.9%; odds ratio, 0.09; 95% confidence interval, 0.01-0.63).

Citing Articles

Trends in insecticide resistance in natural populations of Culex quinquefasciatus and its impact on mosquito fitness in Dschang, West Cameroon.

Poumachu Y, Lontsi-Demano M, Zeb J, Djoufounna J, Djiappi-Tchamen B, Hashem A Parasitol Res. 2025; 124(2):17.

PMID: 39888430 PMC: 11785645. DOI: 10.1007/s00436-025-08457-5.


Evidence of human exposure and associated risk factors to Rift Valley fever in selected districts of Central and Western Zambia.

Kasongamulilo C, Syakalima M, Saasa N, Kainga H, Pandey G, Mukubesa A PLoS One. 2025; 20(1):e0309288.

PMID: 39854363 PMC: 11760628. DOI: 10.1371/journal.pone.0309288.


Seroprevalence of spp. and Rift Valley fever virus infections in communal pastoral cattle at the wildlife-livestock interface, Zambezi region, Namibia.

Madzingira O, Munzel H, Simasiku N, Lucas L, Mwenda E, Chinyoka S Front Vet Sci. 2024; 11:1489815.

PMID: 39726584 PMC: 11670368. DOI: 10.3389/fvets.2024.1489815.


Development of a luminex-based assay for the detection of anti-capripoxvirus and rift valley fever virus antibodies in domestic ruminants.

Berguido F, Settypalli T, Mbuyi C, Bakhom M, van Vuren P, Paweska J Virol J. 2024; 21(1):335.

PMID: 39726039 PMC: 11674245. DOI: 10.1186/s12985-024-02602-9.


A Review of Nonhuman Primate Models of Rift Valley Fever Virus Infection: Progress, Challenge Strains, and Future Directions.

Ebisine K, Quist D, Findlay-Wilson S, Kennedy E, Dowall S Pathogens. 2024; 13(10).

PMID: 39452727 PMC: 11510021. DOI: 10.3390/pathogens13100856.